JAZZ Q1 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$814M+33.9% YoY

Gross Profit

$698M85.8% margin

Operating Income

$88M10.8% margin

Net Income

$2M0.2% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

-9.3%

Cash Flow

Operating Cash Flow

$209M

Free Cash Flow

$197M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$11.8B

Total Liabilities

$8.2B

Stockholders' Equity

$3.6B

Cash & Equivalents

$491M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$814M	$608M	+33.9%
Gross Profit	$698M	$567M	+23.1%
Operating Income	$88M	$162M	-46.0%
Net Income	$2M	$122M	-98.6%

Revenue Segments

Xyrem

$247M31%

Xywav

$186M23%

Epidiolex/Epidyolex

$158M20%

Zepzelca

$59M7%

Rylaze/Enrylaze

$54M7%

Defitelio/Defibrotide

$49M6%

Vyxeos

$34M4%

Sativex

$5M1%

Other Products

$943,0000%

Geographic Segments

UNITED STATES

$741M91%

Europe

$61M7%

Other Countries

$12M1%